Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.

× No keyword cloud information.

13 in total

1. Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model.

Authors: Wen Lin; Tao Ji; Heidi Einolf; Surya Ayalasomayajula; Tsu-Han Lin; Imad Hanna; Tycho Heimbach; Christopher Breen; Venkateswar Jarugula; Handan He
Journal: J Pharm Sci Date: 2017-01-13 Impact factor: 3.534

2. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study.

Authors: Jun Gao; Dafang Zhong; Xiaotao Duan; Xiaoyan Chen
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2007-05-26 Impact factor: 3.205

3. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.

Authors: Imad Hanna; Natalya Alexander; Matthew H Crouthamel; John Davis; Adrienne Natrillo; Phi Tran; Arpine Vapurcuyan; Bing Zhu
Journal: Xenobiotica Date: 2017-03-10 Impact factor: 1.908

4. A method for estimating the probability of adverse drug reactions.

Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875

5. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.

Authors: Surya P Ayalasomayajula; Thomas H Langenickel; Pierre Jordaan; Wei Zhou; Priyamvada Chandra; Diego Albrecht; Parasar Pal; Iris Rajman; Gangadhar Sunkara
Journal: Eur J Clin Pharmacol Date: 2016-05-26 Impact factor: 2.953

Review 6. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Authors: Yoshihisa Shitara; Yuichi Sugiyama
Journal: Pharmacol Ther Date: 2006-05-22 Impact factor: 12.310

7. Rhabdomyolysis: an evaluation of 475 hospitalized patients.

Authors: Giorgia Melli; Vinay Chaudhry; David R Cornblath
Journal: Medicine (Baltimore) Date: 2005-11 Impact factor: 1.889

8. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.

Authors: S G Simonson; P D Martin; P Mitchell; D W Schneck; K C Lasseter; M J Warwick
Journal: Eur J Clin Pharmacol Date: 2003-01-30 Impact factor: 2.953

Review 9. Rosuvastatin: a review of its use in the management of dyslipidemia.

Authors: Lesley J Scott; Monique P Curran; David P Figgitt
Journal: Am J Cardiovasc Drugs Date: 2004 Impact factor: 3.571

10. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Authors: Zhanna Kobalava; Yulia Kotovskaya; Oleg Averkov; Elena Pavlikova; Valentine Moiseev; Diego Albrecht; Priya Chandra; Surya Ayalasomayajula; Margaret F Prescott; Parasar Pal; Thomas H Langenickel; Pierre Jordaan; Iris Rajman
Journal: Cardiovasc Ther Date: 2016-08 Impact factor: 3.023

1 in total

1. Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report.

Authors: Kelvin Shenq Woei Siew; Muhammad Imran Abdul Hafidz; Fatimah Zahrah Binti Mohd Zaidan; Mohd Firdaus Bin Hadi
Journal: Eur Heart J Case Rep Date: 2022-02-22

1 in total